REACT: a randomized trial to assess the efficacy and safety of clazosentan for preventing clinical deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.

Phase III trial of the endothelin antagonist clazosentan in high-clot-burden aSAH.

Highlights

Index entry — verify clinical detail against the primary source.

Related conditions

For learning and professional reference; not a patient-specific recommendation. How we prepare content.